MCL Literature Feed

This study compares bendamustine-rituximab (BR) versus R-CHOP as initial therapy for transplant-ineligible MCL patients, providing evidence to guide frontline treatment selection in this common clinical setting.

A rare B-ALL subtype with a MEF2D::BCL9 fusion can mimic blastoid MCL by co-expressing CD5 and SOX11, highlighting a critical diagnostic pitfall requiring molecular confirmation.

Overexpression of IL-16 drives BTKi resistance via the CD9/NF-κB/AKT axis in MCL models, presenting a novel therapeutic target to overcome treatment failure and restore drug sensitivity.

In older relapsed/refractory MCL patients, brexucabtagene autoleucel offers superior 1-year overall survival and lower non-relapse mortality versus allogeneic transplant, though long-term outcomes are similar, guiding treatment selection.

In frontline MCL, pre-treatment ctDNA levels and TP53 mutations predict poor survival, while post-treatment ctDNA clearance identifies patients with favorable outcomes, establishing its clinical utility for prognosis.

This review provides a practical guide for differentiating aggressive B-cell lymphomas, including mantle cell lymphoma, emphasizing the integration of morphology, immunohistochemistry, and molecular testing for accurate diagnosis and classification.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

High p62 expression predicts poor survival in MCL by upregulating CCND1 transcription via Nrf2, identifying p62 as a novel prognostic biomarker and potential non-BTK/BCL2 therapeutic target.

This phase 2 trial shows ibrutinib is effective in high-risk, previously untreated smoldering MCL, suggesting early intervention with a BTKi can delay progression in this traditionally observed population.

A novel single-cell genomic research model tracks MCL clonal evolution, providing a high-resolution tool to dissect mechanisms of therapeutic resistance and identify potential new targets.

This review synthesizes mechanisms of BTKi resistance and highlights next-generation strategies like noncovalent BTKi and PROTACs to overcome this critical challenge in relapsed/refractory MCL.

NGS-detected TP53 mutations are a major clinical risk factor, enabling precise patient stratification to guide initial therapy selection and identify candidates for novel agents.

A novel high-performance liquid chromatography-ultraviolet (HPLC-UV) assay was developed to measure pirtobrutinib levels, enabling therapeutic drug monitoring to potentially optimize dosing in MCL patients.

The chemotherapy-free triplet of acalabrutinib (BTKi), umbralisib (PI3Ki), and ublituximab (anti-CD20) achieved high response and MRD-negativity rates in untreated MCL, presenting a novel frontline option.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

This review provides a practical guide for clinicians on the approved indications and real-world application of anti-CD19 CAR-T cell therapy for mantle cell lymphoma.

Optical genome mapping reveals diverse cryptic CCND1/2 rearrangements in ~10% of MCLs lacking the classic t(11;14), improving diagnosis and identifying high genomic complexity associated with poor outcomes.

This case report of primary colonic MCL presenting with intussusception highlights surgery's crucial role in diagnosis and managing complications for rare, localized extranodal disease before systemic therapy.

Optical genome mapping detects additional clinically significant genomic aberrations in 8% of mantle cell lymphoma cases compared to standard cytogenetics, potentially improving risk stratification.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

In young, fit MCL patients undergoing frontline autotransplant, large clonal hematopoiesis clones (VAF ≥10%) at baseline are a novel biomarker for worse progression-free and overall survival.

The novel TBL1X inhibitor tegavivint induces DNA damage and synergizes with PARP inhibitors in preclinical MCL models, establishing TBL1X as a new therapeutic target for genomic instability.

This case report describes a rare CCND1-negative mantle cell lymphoma presenting atypically as leukemia, highlighting the need to consider this diagnosis despite the absence of the classic translocation.

This case series reports an incidental MCL diagnosis from a cervical lymph node during thyroid cancer surgery, underscoring the need for thorough pathological evaluation in atypical presentations.

The CD20xCD3 bispecific antibody glofitamab induces high and durable complete response rates in heavily pretreated relapsed/refractory MCL, providing a new off-the-shelf immunotherapy option post-BTKi failure.

This correspondence provides expert commentary and clarification on the pivotal trial data for the bispecific antibody glofitamab in patients with relapsed/refractory mantle cell lymphoma.

This review clarifies updated WHO-5 diagnostic criteria for high-grade B-cell lymphoma, emphasizing the crucial pathologic and genetic distinction from blastoid mantle cell lymphoma to ensure correct patient management.

This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.

This paper describes a rare MCL variant with an intrasinusoidal bone marrow pattern and prolymphocytoid circulating cells, highlighting an unusual presentation that creates diagnostic challenges for pathologists.

This case report on extranodal marginal zone lymphoma is not relevant to mantle cell lymphoma, as it discusses a different B-cell non-Hodgkin lymphoma subtype.